LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.43 USD | +1.55% |
|
+3.53% | 0.00% |
| 15/04 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| 15/04 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | 20.46M 1.71B | Capitalization | 420M 35.01B |
|---|---|---|---|---|---|
| Net income 2024 * | -55M -4.59B | Net income 2025 * | -70M -5.84B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 20.5 x |
| P/E ratio 2024 * |
-7.51
x | P/E ratio 2025 * |
-6.75
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.55% | ||
| 1 week | +3.53% | ||
| Current month | +3.53% | ||
| 1 month | -19.18% |
1 week
15.61
16.79
1 month
15.0522.07
Current year
15.0524.59
1 year
15.0524.59
3 years
15.0524.59
5 years
15.0524.59
10 years
15.0524.59
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 16.43 | +1.55% | 189,749 |
| 06/24/06 | 16.18 | -1.70% | 287,359 |
| 03/24/03 | 16.46 | +0.30% | 202,957 |
| 02/24/02 | 16.41 | +3.80% | 188,715 |
| 01/24/01 | 15.81 | -0.38% | 91,717 |
Delayed Quote Nasdaq, May 08, 2024 at 01:30 am IST
More quotes
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Calendar
08/05/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.43
USD
Average target price
36.75
USD
Spread / Average Target
+123.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 420M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +8.88% | 23.47B | |
| -13.89% | 21.9B | |
| -5.99% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- LENZ Stock